{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:53:56Z","timestamp":1787241236096,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.japh.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T11:47:55Z","timestamp":1646999275000},"page":"1422-1429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-5251","authenticated-orcid":false,"given":"Haley","family":"Pals","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-5768","authenticated-orcid":false,"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2022.03.006_bib1","author":"Ahmad"},{"key":"10.1016\/j.japh.2022.03.006_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.drugalcdep.2015.04.002","article-title":"Trends and characteristics of heroin overdoses in Wisconsin, 2003\u20132012","volume":"152","author":"Meiman","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2022.03.006_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/SAR.S116720","article-title":"Substance use disorders in military veterans: prevalence and treatment challenges","volume":"8","author":"Teeters","year":"2017","journal-title":"Subst Abuse Rehabil"},{"issue":"5","key":"10.1016\/j.japh.2022.03.006_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/papr.12097","article-title":"Prevalence of diagnosed opioid abuse and its economic burden in the Veterans Health Administration","volume":"14","author":"Baser","year":"2014","journal-title":"Pain Pract"},{"issue":"3","key":"10.1016\/j.japh.2022.03.006_bib5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.amepre.2021.02.026","article-title":"Association between buprenorphine for opioid use disorder and mortality risk","volume":"61","author":"Vakkalanka","year":"2021","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.japh.2022.03.006_bib6","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.japh.2022.03.006_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.japh.2022.03.006_bib9","series-title":"Drug addiction treatment act of 2000, H.R. 2634, 106th Congress","year":"1999"},{"issue":"1","key":"10.1016\/j.japh.2022.03.006_bib15","first-page":"87","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder","volume":"38","author":"Andrilla","year":"2022","journal-title":"J\u00a0Rural Health"},{"issue":"2","key":"10.1016\/j.japh.2022.03.006_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis","volume":"24","author":"Amiri","year":"2021","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.japh.2022.03.006_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/ajad.12805","article-title":"Expanding access to buprenorphine treatment in rural areas with the use of telemedicine","volume":"27","author":"Weintraub","year":"2018","journal-title":"Am J Addict"},{"key":"10.1016\/j.japh.2022.03.006_bib19","first-page":"1","article-title":"Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine","author":"Brunet","year":"2020","journal-title":"Subst Abus"},{"key":"10.1016\/j.japh.2022.03.006_bib20","doi-asserted-by":"crossref","first-page":"108272","DOI":"10.1016\/j.jsat.2020.108272","article-title":"Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic","volume":"124","author":"Wang","year":"2021","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"2","key":"10.1016\/j.japh.2022.03.006_bib21","doi-asserted-by":"crossref","first-page":"106603","DOI":"10.1016\/j.ypmed.2021.106603","article-title":"The intertwined expansion of telehealth and buprenorphine access from a prescriber hub","volume":"152","author":"Moore","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.japh.2022.03.006_bib22","doi-asserted-by":"crossref","first-page":"108543","DOI":"10.1016\/j.jsat.2021.108543","article-title":"The COVID-19 pandemic and opioid use disorder: expanding treatment with buprenorphine, and combining safety precautions with telehealth","volume":"133","author":"Cales","year":"2022","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"3","key":"10.1016\/j.japh.2022.03.006_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1468-0009.12137","article-title":"Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties: where is buprenorphine dispensed to treat opioid use disorders?","volume":"93","author":"Stein","year":"2015","journal-title":"Milbank Q"},{"issue":"2","key":"10.1016\/j.japh.2022.03.006_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/08897077.2020.1752351","article-title":"Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment","volume":"41","author":"Green","year":"2020","journal-title":"Subst Abus"},{"issue":"3","key":"10.1016\/j.japh.2022.03.006_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/08897077.2020.1787300","article-title":"Medication treatment for opioid use disorder and community pharmacy: expanding care during a national epidemic and global pandemic","volume":"41","author":"Cochran","year":"2020","journal-title":"Subst Abus"},{"issue":"1","key":"10.1016\/j.japh.2022.03.006_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9740\/mhc.2015.01.001","article-title":"Improving medication-related outcomes for patients with psychiatric and neurologic disorders: value of psychiatric pharmacists as part of the health care team","volume":"5","author":"Goldstone","year":"2015","journal-title":"Mental Health Clinician"},{"issue":"1","key":"10.1016\/j.japh.2022.03.006_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.9740\/mhc.2021.01.035","article-title":"Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine\/naloxone","volume":"11","author":"Mailloux","year":"2021","journal-title":"Mental Health Clinician"},{"issue":"2","key":"10.1016\/j.japh.2022.03.006_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1331\/JAPhA.2015.14177","article-title":"Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients","volume":"55","author":"DiPaula","year":"2015","journal-title":"J.\u00a0Am. Pharm. Assoc. (2003)"},{"issue":"7","key":"10.1016\/j.japh.2022.03.006_bib29","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network","volume":"116","author":"Wu","year":"2021","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.japh.2022.03.006_bib30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/ajhp\/zxaa405","article-title":"Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder","volume":"78","author":"DeRonne","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.japh.2022.03.006_bib31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5055\/jom.2014.0204","article-title":"Implementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and chronic pain patients using opioids nonmedically","volume":"10","author":"Suzuki","year":"2014","journal-title":"J\u00a0Opioid Manag"},{"issue":"8","key":"10.1016\/j.japh.2022.03.006_bib32","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/ajhp\/zxab011","article-title":"Increasing rural patient access using clinical pharmacy specialist providers: successful practice integration within the Department of Veterans Affairs","volume":"78","author":"Groppi","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"64","key":"10.1016\/j.japh.2022.03.006_bib33","first-page":"15595","article-title":"Implementation of the Ryan Haight online pharmacy consumer protection act of 2008. Interim final rule with request for comments","volume":"74","year":"2009","journal-title":"Fed Regist"},{"key":"10.1016\/j.japh.2022.03.006_bib34","doi-asserted-by":"crossref","first-page":"108011","DOI":"10.1016\/j.jsat.2020.108011","article-title":"Appointment wait-times and arrival for patients at a low-barrier access addiction clinic","volume":"114","author":"Roy","year":"2020","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.japh.2022.03.006_bib35","doi-asserted-by":"crossref","first-page":"108140","DOI":"10.1016\/j.jsat.2020.108140","article-title":"Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program","volume":"119","author":"Jakubowski","year":"2020","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"10","key":"10.1016\/j.japh.2022.03.006_bib36","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1176\/appi.ajp.2020.19090901","article-title":"Well-being, burnout, and depression among North American psychiatrists: the state of our profession","volume":"177","author":"Summers","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.japh.2022.03.006_bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11606-020-06175-5","article-title":"Spreading addictions care across Oregon\u2019s Rural and Community Hospitals: mixed-methods evaluation of an interprofessional Telementoring ECHO program","volume":"36","author":"Englander","year":"2021","journal-title":"J\u00a0Gen Intern Med"},{"issue":"1","key":"10.1016\/j.japh.2022.03.006_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/08897077.2019.1694617","article-title":"Barriers and perceived usefulness of an ECHO intervention for office-based buprenorphine treatment for opioid use disorder in North Carolina: a qualitative study","volume":"42","author":"Shea","year":"2021","journal-title":"Subst Abus"},{"issue":"3","key":"10.1016\/j.japh.2022.03.006_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","article-title":"Stepped care for opioid use disorder train the trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within veteran health affairs\u2019 facilities","volume":"41","author":"Gordon","year":"2020","journal-title":"Subst Abus"},{"issue":"193","key":"10.1016\/j.japh.2022.03.006_bib40","first-page":"61613","article-title":"Role of authorized agents in communicating controlled substance prescriptions to pharmacies","volume":"75","year":"2010","journal-title":"Fed Regist"},{"issue":"10","key":"10.1016\/j.japh.2022.03.006_bib42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ajhp\/zxaa060","article-title":"A\u00a0Physician-pharmacist collaborative care model to prevent opioid misuse","volume":"77","author":"Lagisetty","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.japh.2022.03.006_bib43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","article-title":"Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: x the x waiver","volume":"76","author":"Fiscella","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.japh.2022.03.006_bib44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/08897077.2019.1694618","article-title":"Pharmacy: addressing substance use in the 21st century","volume":"40","author":"Bratberg","year":"2019","journal-title":"Subst Abus"},{"issue":"7","key":"10.1016\/j.japh.2022.03.006_bib45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ajhp\/zxab003","article-title":"Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic","volume":"78","author":"Peckham","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.japh.2022.03.006_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drugpo.2015.11.006","article-title":"Community pharmacy services for people with drug problems over two decades in Scotland: implications for future development","volume":"27","author":"Matheson","year":"2016","journal-title":"Int J Drug Policy"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:49:53Z","timestamp":1761544193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1544319122000784"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.03.006","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}